Browsing category:


On November 14th, 2012 Zomig went off-patent, opening the door for generic versions of this formidable product. As an efficacious treatment for patients suffering from migraines with or without auras, zolmitriptan is also known as Zomig, marketed by AstraZeneca. Offered in both oral and orally disintegrating tablets, in 2.5 or 5 milligram tablets, zolmitriptan has[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service